Patients with chronic kidney disease and metabolic acidosis treated with sodium bicarbonate experienced decreased risks of a doubling of serum creatinine, initiation of renal replacement therapy, and death.
Proton pump inhibitor use by patients with CKD stage 3 to 5 is associated with 54% and 35% increased risks of acute kidney injury and death, respectively, a study found.
Compared with CKD stage 3a, CKD stages 3b, 4, and 5 were associated with significant 1.5-, 2.4-, and 5.4-fold increased risks of anemia.
Compared with individuals who had an eGFR (in mL/min/1.73 m2) above 90, those with an eGFR of 30-16 and 15 or below had significant 2.4- and 3.76-fold increased risks of bacteremia.
Hyperkalemia in patients undergoing cardiac surgery is associated with increases risks for postoperative death, cerebrovascular accidents, and need for dialysis.
Type 1 diabetes onset before the age of 14 years is independently associated with a greater risk of kidney disease compared with later age at onset, according to a new study.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
In Michigan, approximately 1 in 4 hospitalized patients with a PICC placement had CKD stage 3b or higher, contrary to guidelines.
In a study of veterans taking proton pump inhibitors, 4 and 15 extra deaths per 1000 patients occurred due to CKD and CVD, respectively.
In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.